Celcuity (CELC) Lifted to “Buy” at ValuEngine
ValuEngine upgraded shares of Celcuity (NASDAQ:CELC) from a hold rating to a buy rating in a research note issued to investors on Friday.
A number of other equities analysts have also issued reports on the stock. HC Wainwright started coverage on shares of Celcuity in a research report on Tuesday, November 20th. They set a buy rating and a $36.00 target price on the stock. Zacks Investment Research raised shares of Celcuity from a hold rating to a buy rating and set a $26.00 target price on the stock in a research report on Thursday, February 28th.
Shares of CELC stock opened at $20.07 on Friday. Celcuity has a 1 year low of $13.16 and a 1 year high of $31.00. The firm has a market cap of $209.18 million, a P/E ratio of -27.12 and a beta of 0.24.
Celcuity Inc, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer.
Recommended Story: Candlestick
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.